OncoMatch/Clinical Trials/NCT06645808
PET-imaging of Two Vartumabs in Patients With Solid Tumors
Is NCT06645808 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including 89Zr-DFO-N-Suc-F8scFv and 89Zr-DFO-N-Suc-C9scFv for solid tumor.
Treatment: 89Zr-DFO-N-Suc-F8scFv · 89Zr-DFO-N-Suc-C9scFv — VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS). Oncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identified by VAR2 Pharmaceuticals as expressed during fetal development. Oncofetal CS reappears in the vast majority of cancers while remaining largely absent from normal tissues. VAR2 Pharmaceuticals recently developed antibodies specific for oncofetal CS. VARTUTRACE uses two of these as radiolabeled antibody fragments to study biodistribution, tumor accumulation, pharmacodynamics and clearance pathways in a diverse patient population.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Colorectal Cancer
Osteosarcoma
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Esophageal Carcinoma
Gastric Cancer
Urothelial Carcinoma
Glioblastoma
Sarcoma
Breast Carcinoma
Disease stage
Required: Stage I, II, III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
INR or APTT 1.5x ULN (if not on anticoagulation); serum albumin 35 g/L
Kidney function
eGFR (based on plasma-creatinine) = 30 mL/min
Liver function
AST, ALT, and alkaline phosphatase 2.5x ULN; serum bilirubin 2.0x ULN (Gilbert disease: 3x ULN allowed)
Cardiac function
overtly healthy based on ECG at screening; LVEF 35%; no prolonged QTcF (450 ms), no cardiac arrhythmias or significant ECG abnormalities
Adequate liver- and kidney function, defined by the following laboratory results obtained during screening visit: AST, ALT, and alkaline phosphatase 2.5x ULN; serum bilirubin 2.0x ULN (Gilbert disease: 3x ULN allowed); INR or APTT 1.5x ULN (if not on anticoagulation); eGFR (based on plasma-creatinine) = 30 mL/min; serum albumin 35 g/L; overtly healthy based on ECG at screening; LVEF 35%; no prolonged QTcF (450 ms), no cardiac arrhythmias or significant ECG abnormalities
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify